靶向 CD38 与 SLAMF7、具有独立信号传导的双 CAR-T 细胞在多发性骨髓瘤中显示临床前疗效与安全性

Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple My

靶向B细胞成熟抗原（BCMA）的嵌合抗原受体（CAR）T细胞疗法治疗多发性骨髓瘤可诱导高总体缓解率。